Boston Scientific's Precision Plus spinal cord stimulator gains CE mark

13 September 2012

Boston Scientific Corporation has received European approval for use of its Precision Plus spinal cord stimulator (SCS) System, the world's first rechargeable SCS device, in peripheral nerve stimulation for patients with chronic intractable pain of the trunk.

Peripheral nerve stimulation provides physicians and patients with an additional treatment option for managing chronic intractable pain of the trunk by stimulating peripheral nerves through a small surgically implantable device.

"I am pleased to learn the Precision Plus SCS System has received CE Mark approval for peripheral nerve stimulation," said Dr. David Abejón, consultant anaesthetist at Hospital Universitario Puerta de Hierro Majadahonda, Madrid. "Based on my clinical experience and research with peripheral nerve stimulation therapy to date, this technique seems to be a promising treatment option in the field of chronic intractable pain management."

Chronic intractable pain is continuous pain has lasted more than six months. Living in constant pain for an extended period time can have a devastating impact to quality of life for many patients. Without relief, or the hope for relief, many patients lose the ability to sleep, work, and function normally.

"Chronic pain affects nearly 95 million adults throughout Europe," said Michael Onuscheck, senior vice president and president of Europe, Middle East and Africa at Boston Scientific. "Expanding our neuromodulation portfolio to include peripheral nerve stimulation with the PRECISION PLUS SCS System continues our commitment to providing physicians and patients with multiple treatment options for the management of this debilitating condition."


To top